In CML patients, resistance to TKi can result from two major mechanisms: (i) occurrence of TKi-resistant BCR-ABL1 mutations; (ii) enhancement of BCR-ABL1-independent pro-survival pathways. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.